Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
inactivated split influenza vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| inactivated split influenza vaccine | BIOLOGICAL | 1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010 |
Inclusion Criteria: Subjects eligible for enrollment into this study are male and female adults who are 1. ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry 2. Able to comply with all study requirements 3. In good health as determined by: * M...
Inactivated split influenza vaccine is used for seasonal influenza. It is an investigational vaccine being studied for the prevention of seasonal flu. The vaccine is designed to elicit an immune response against the influenza strains included in the seasonal composition.
Inactivated split influenza vaccine is being developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity for seasonal influenza.
Inactivated split influenza vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 3 trial has been completed, but the vaccine remains under investigation for seasonal influenza.
Inactivated split influenza vaccine has one completed Phase 3 trial, NCT00945841, titled 'Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010'. The trial enrolled 126 healthy volunteers aged 18 years and older in Germany.
No, inactivated split influenza vaccine is not a monoclonal antibody. It is classified as a vaccine modality, specifically an inactivated split vaccine. The vaccine is designed to induce immunity against seasonal influenza, whereas monoclonal antibodies are laboratory-made proteins that target specific antigens.